Immunohistochemical analysis of postmortem human brain of patient with Alzheimer's disease presents a significantly higher Kv1.3 staining intensity, leading to conclude that potential therapeutic targets could be the KV1.3 channel inhibition [77]. This evidence concerns the gene KCNA3 and Alzheimer disease.